Stay updated with breaking news from Ionis Core. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) have earned a consensus rating of “Hold” from the fourteen ratings firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating on the company. […]
Sumitomo Mitsui Trust Holdings Inc. decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 23.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 336,732 shares of the company’s stock after selling 100,444 shares during the period. Sumitomo Mitsui […]
AtonRa Partners reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,875 shares of the company’s stock after selling 3,753 shares during the period. AtonRa Partners’ holdings in […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) traded down 3.9% during trading on Tuesday . The company traded as low as $36.23 and last traded at $36.31. 249,701 shares were traded during trading, a decline of 74% from the average session volume of 942,465 shares. The stock had previously closed at $37.78. Wall Street Analyst […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) had its target price boosted by Morgan Stanley from $40.00 to $42.00 in a report released on Tuesday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock. A number of other brokerages also recently weighed in on IONS. Needham & Company LLC reiterated a […]